A new study found that adults with alcohol use disorder (AUD) who started treatment with GLP-1 receptor agonists like semaglutide and tirzepatide had significantly fewer alcohol-related hospitalizations compared to those on other diabetes or obesity medications. The study analyzed health records of over 40,000 adults with AUD and either type 2 diabetes or obesity, showing a 22-32% reduction in hospitalization risk. Researchers used advanced methods to mimic randomized trials but caution that further clinical trials are needed to confirm causality. These findings suggest GLP-1 receptor agonists could play a role in reducing alcohol-related harm, highlighting a potential new avenue for treatment.
D.R. Horton reported Q3 earnings per share of $3.20, beating estimates, and revenues of $9.23 billion, slightly above expectations. Goldman Sachs raised its price target to $190 and maintained a "Buy" rating, signaling strong growth potential. Despit...
Interactive Brokers reported a strong Q2 with diluted EPS of $0.69 and net revenues of $1.90 billion, both exceeding analyst expectations. The company saw a 34% increase in client accounts and a 40% rise in client equity, driven by higher trading act...
United Rentals is set to report its Q2 2026 earnings on July 22, with analysts forecasting an 11.5% rise in earnings per share to $11.67 and a 7.3% increase in revenue to $4.23 billion. The growth is driven by strong rental demand and efficient equip...
Analyst firm BTIG initiated a Buy rating on Philip Morris International, with the stock trading at $188.04. They project strong Q2 earnings of $2.05 per share and revenue growth to $10.64 billion, up from last year. The company also offers an attract...
A director of City Holding Co increased their stake by purchasing 110 shares at $134.55 each, signaling confidence in the company. The stock has risen 11.27% year-to-date and is trading near its 52-week high, reflecting strong market performance. Cit...
